American Society of Hirudotherapy

Hni-Hirudin

Hirudo nipponia salivary-gland hirudin variant identified by transcriptome + in situ hybridisation — Kim 2024 and Shi 2023 (Pichia pastoris recombinant production, 14,000 ATU/mL).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Hni-Hirudin7 kDa
Molecular weight (kilodaltons) of Hni-Hirudin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

Hni-Hirudin's antithrombin activity in recombinant assays does NOT establish clinical efficacy. No FDA-approved derivative; H. nipponia is not on the FDA K040187 cleared device species list.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
7,000 Da
Source species
Hirudo nipponia
Discovered
2023 · Shi P et al.; Kim JH et al.

Biological Targets

  • → thrombin (Factor IIa)

Key Citations

  1. Shi P et al. (2023), Sci Rep · PMID 36973525
  2. Kim JH et al. (2024), Dev Comp Immunol · PMID 38158145

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.